Next-gen Covid vaccine hopefuls part ways with K Street

During the first year and a half of the pandemic, a handful of small companies developing next-generation Covid-19 vaccines hired lobbyists in hopes of winning contracts to fund research, manufacturing and testing. Megan R. Wilson talks with host Ben Leonard about why, nearly three years in, many have abandoned their Washington, D.C., footprint. Learn more about your ad choices. Visit megaphone.fm/adchoices